Screening and care for fear that breast or lung cancer will come back or get worse at Institut Curie
Fear of Cancer Recurrence: Prevalence, Lived Experience and Satisfaction of Supportive Care Needs in the Hospital Care Pathway. A Mixed Method Study.
This project will test brief screening methods to find people at Institut Curie with severe fear that their breast or lung cancer will come back or progress so they can get appropriate help.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Institut Curie Academic / other |
| Locations | 1 site (Paris) |
| Trial ID | NCT07357311 on ClinicalTrials.gov |
What this trial studies
This observational project will measure how common severe fear of cancer recurrence or progression (FCR) is among French-speaking breast and lung cancer patients treated at Institut Curie. Eligible adults will complete the Fear of Recurrence Inventory (FCRI) and related questionnaires at least three months after finishing treatment or three months into a first-line metastatic therapy. The team will seek threshold scores for the FCRI 9-item severity scale by cancer type and evaluate whether a single FCRI item can reliably flag high FCR for routine or digital screening. The goal is to culturally validate shorter screening tools in French and identify patients who need a targeted psychotherapeutic response.
Who should consider this trial
Good fit: Adults (18+) with a diagnosis of breast or lung cancer — including localized, locoregional, or metastatic disease — who are at least three months post-treatment or three months into first-line metastatic therapy and can read French are the intended participants.
Not a fit: Patients who cannot read French, cannot complete questionnaires, are under guardianship or detention, or who are enrolled in conflicting patient-reported outcome studies are unlikely to benefit or be eligible.
Why it matters
Potential benefit: If successful, this work could enable simpler, earlier detection of severe FCR so more patients receive timely psychological support and improved quality of life.
How similar studies have performed: The FCRI is widely validated and shorter screening items have been used in other settings, but established cut-offs for French-speaking breast and lung cancer populations and systematic study in metastatic patients remain limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Aged 18 or over * Clinical or pathological diagnosis of primary or recurrence of a localized/loco-regional or metastatic breast cancer, or a stage 1 or 2, or stage 3 or 4 lung cancer; or a breast or lung cancer metastatic progression * Three months after completing treatment or three months after the start of a first treatment line for metastatic progression * Able to comply with the scheduled assessment and interviews * Able to read and understand the questionnaires' language (i.e. French) Exclusion Criteria: * Participating in another patient-reported outcome study interfering with the present study * Any social, medical or psychological condition hindering questionnaire completion * Being deprived of personal liberty or under guardianship
Where this trial is running
Paris
- Institut Curie — Paris, France (Recruiting)
Study contacts
- Study coordinator: Anne Bredart, Ph.D
- Email: anne.bredart@curie.fr
- Phone: +33 1 44 32 43 50
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.